A new type of CAR-T therapy that targets the protein CD22 helped achieve remission in nearly 60 percent of leukemia patients who had failed or relapsed on other treatments, according to a paper published in Nature Medicine.
Acquired mutations in blood stem cells—whether arising from smoking, exposure to toxins or even normal aging—interact with mutations passed down by parents in important ways that influence a person’s lifetime risk of developing blood cancer, a study led by researchers at WashU Medicine found.
